A phase I, open-label multi-center, dose escalation study of AMN107 [nilotinib] in combination with imatinib in adult patients with Ph+ chronic myelogenous leukemia in chronic phase following a sub-optimal response to imatinib mesylate

Trial Profile

A phase I, open-label multi-center, dose escalation study of AMN107 [nilotinib] in combination with imatinib in adult patients with Ph+ chronic myelogenous leukemia in chronic phase following a sub-optimal response to imatinib mesylate

Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Aug 2006

At a glance

  • Drugs Imatinib; Nilotinib
  • Indications Chronic myeloid leukaemia
  • Focus Adverse reactions; Pharmacogenomic
  • Most Recent Events

    • 01 Aug 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top